Psoriatic arthritis
Study and biobank

Psoriatic arthritis (PsA) is a highly varied condition, ranging from relatively mild disease limited to one area to a severe arthritis affecting most joints. However, it is not currently possible to predict how PsA will develop in an individual, making it difficult to determine optimal treatment in early disease. Early stratification of patients with PsA is becoming particularly important as new therapies become available which preferentially target specific features of the disease. In order to help address this, adult patients in Scotland with a new or recent onset (≤4 years) diagnosis of PsA will be invited to take part in the SOPHOS national cohort.

Study objectives

(i) To generate a molecular signature that describes and predicts the evolving psoriatic arthritis phenotype.

(ii) To compare and contrast this molecular signature with those being developed in Rheumatoid Arthritis
(using comparator patients from the Scottish Early Rheumatoid Arthritis (SERA) cohort.


A prospective observational cohort and clinical laboratory study.


300 patients with a recent diagnosis (minimum 150 with new diagnosis) of PsA attending rheumatology departments throughout Scotland. The first patient was recruited on 18/09/17.


Adult patients (≥18 years) with either a new or recent (within 4 years of symptom onset) diagnosis of PsA made by a rheumatologist.

What is a Biobank?

It is a carefully regulated ‘bank’ of tissue or blood samples that are being stored for future analysis.